RxC Team

RxC Team

The RxC team has deep life sciences expertise in corporate development, new product planning, and commercial excellence. 


Subbarao Jayanthi, Managing Partner 

At RxC International, our mission is to collaborate with clients to grow their business.  RxC team has a unique blend of strategic and operational expertise to assist clients in capitalizing on growth opportunities and to bring products to patients faster. 

Subbarao Jayanthi has over 20 years of strategic consulting and operational experience in the life sciences sector. He has advised board members and executives at leading pharma and biotech companies. His areas of expertise include corporate strategy, life cycle management and M&A. He has executed several successful financial transactions for clients.  

He has authored books on Commercialization of Pharmaceutical and Biotechnology Products in USA and Biopharma Value Chain Management. These publications focus on helping BioPharma companies navigate through the complexity at each stage of the value chain.  

Subbarao has previously held leadership positions at BCG, DSI & others. He has undergraduate and graduate degrees in engineering along with an M.B.A. from Kellogg School of Management at Northwestern University.



Rich Tinsley, Strategy Partner 

“RxC’s combination of operational and consulting experiences provide a valuable perspective with which to understand the needs and pressures of client executives and the businesses they are managing.” 

Rich Tinsley has over 20 years of life sciences consulting experience and is a recognized leader in areas of strategy, commercialization, lifecycle management and sophisticated forecast modeling.  Rich has deep expertise in ACO’s and has been a speaker on the Future of Healthcare in the US. 

Prior to joining RxC International, Rich was a Senior Partner at Putnam Associates and also worked for Bain & Company where he advised senior executives at 6 of the top 10 Biopharma companies and many smaller ones.  Rich has worked in rare diseases, HIV, oncology, neurology, diagnostics, and many other specialty markets.  Rich served as COO of a financial services company overseeing $3.6B in client assets and a CFO of a dental technology company.  In both positions, Rich was responsible for setting the overall firm’s marketing strategy, optimizing its sales force investment, and managing the back office operations.  

Currently, Rich serves on several boards including Massachusetts Board of Registration in Pharmacy, Sudbury Board of Education, and Diagnostyx, Inc.  Rich led the expert panel on gene therapy at NYBIO 2016.  His publications include several white papers and journal articles. 

Rich has a B.S. in Economics and Finance from The Wharton School at University of Pennsylvania, and an M.B.A. from Stanford University Graduate School of Business. 



Jim Hoyes, Executive Partner 

Today, both the opportunities and challenges for biopharma companies are many – the growing complexity and increasing inter-dependencies require the right perspective and a steady hand.  

Jim Hoyes has a long track record of creating strategies and driving exceptional performance in the life sciences sector. In addition to providing advisory services to clients, Jim focuses on corporate development initiatives in the life sciences sector and the implementation of key strategic initiatives designed to scale up the firm’s global operations. Jim has deep expertise in all areas of corporate development and commercialization of pharmaceutical and biotechnology products. He has led a number of financial transactions including licensing and M&A deals. 

Prior to joining RxC International, Jim served as President of EMD Serono, leading the company in consistent double-digit revenue gains. Prior to EMD Serono, he held leadership positions with several leading biopharma companies, including chief commercial officer at Serono, vice president of Marketing at Elan, and vice president of Managed Markets at Sanofi. 

Jim is on the board of MassBIO and has served on the boards of PhRMA and BIO. Jim is also involved with the boards of several non-profit community service organizations in the greater Boston area.  Jim received a B.S. in Biology from Penn State University.   



Nick DeSanctis, Executive Partner  

"Whether it's a new corporate level process or an innovative product strategy, successful development and implementation can often be met with many challenges. At RxC International we have corporate level executives with the first-hand experience and proven track records of success to understand and proactively reduce these challenges. Our pledge to work with you through successful implementation is our guarantee of satisfaction.'” 

Nick DeSanctis is a pharmaceutical executive with over 25 years of leadership experience in the industry and is an expert in New Product Planning and driving portfolio value through areas such as Portfolio Management, Life Cycle Management, Target Value Profile Development and Therapeutic Area Strategy. Nick also has extensive global experience in developing strong business – R&D cross functional planning and integrated decision making.  His background includes building and leading the New Product Planning function, strategic pipeline development, global and US based marketing and field operations experience. 

Prior to RxC International, Nick served as Vice President of New Product Planning for Daiichi Sankyo where he led the formation of the New Product Planning function. He worked closely with R&D on early to late stage go/no-go development decisions, product prioritization and therapeutic area strategy.  He was also responsible for the identification and business analysis of in-licensing opportunities necessary to build strategic alliances.  Nick played a key role in both early business planning and pipeline decision making as a core member of several executive management committees at Daiichi Sankyo Inc. Earlier in his career Nick worked at Bristol-Myers Squibb where he held leadership positions in the Worldwide Franchise Management Group, US Marketing and Field Management. During his tenure at BMS he was the recipient of multiple management performance awards.  

Nick has a B.S. in Pharmacy and an M.B.A. in Marketing from Rutgers University.



Jose De Leon, Executive Partner  

 “If you fail to Plan, you Plan to fail. RxC team’s commercialization expertise is invaluable for clients as they plan and execute product launches in this increasingly complex healthcare environment.” 

Jose is an expert in new product planning and early commercialization of products in the pharmaceutical industry.  He has an unparalleled expertise in launching products in all major regions of the world.  He has a proven track record of managing Global Product Marketing teams as well as Global Product Launches, Lifecycle management and Global Strategic Planning.  

He also has expert marketing knowledge of life sciences business related to platelet inhibitors, anticoagulants, atherosclerosis and a broad cardiology product development and launch experience. Jose also managed global launches of diabetes and anti-atherosclerotic agents.  He led the global launches of major cholesterol lowering products such as Lipitor, Lopid and Pravachol. He has a proven track record of managing Global Product Marketing teams as well as Global Product Launches, Lifecycle management and Global Strategic Planning. He also has a broad international experience having served as General Manager for Parke Davis in both Latin America, Europe and the US. 

Prior to joining RxC, Jose was an Executive Director of New Product Planning for Daiichi Sankyo Inc., and Senior Director of Global New Product Planning for Warner Lambert, Parke Davis (now part of Pfizer). Jose has a double major in Chemistry and Biology from the University of Puerto Rico.



Frank Koos, Executive Partner - Head of Business Development

“RxC International is committed to producing high quality solutions and outcomes for clients. The firm has deep expertise in translating strategies into actions and ensuring operational success in all areas of new product development and commercialization.” 

As the head of business development for RxC International, Frank is responsible for building new relationships and nurturing continuing client relationships.  He has over 20 years of leadership experience in pharmaceutical marketing, sales and business development.  Frank is a well-known expert in all aspects of sales force leadership including high value B2B, consultative solution sales, high growth revenue attainment, team structure, strategic account management, client satisfaction and sales analytics and reporting. 

Frank brings to RxC expertise and knowledge from Alitair Pharmaceuticals, Patient Point, MiddleBrook, Reckitt Benckiser, Adams Respiratory Therapeutics, IMS Health, and Johnson & Johnson.  Frank has been involved with multiple product launches, M&A transactions, as well as sales force development and marketing initiatives.  His therapeutic experience includes respiratory, anti-infective, women’s health, dermatology, as well as Rx to OTC conversion. 

Frank was 1st lieutenant with U.S. Armed Services.  Frank graduated from Lehigh University with a B.A. in International Relations.



Kevin Kirkemo, Management Consultant 

“My recent engagements have allowed me to solve interesting problems focused around market evaluation and launch planning, lifecycle management and portfolio strategy, as well as operational support for manufacturing, pharmacovigilance and medical affairs.” 

Kevin Kirkemo is a management consultant and has supported a number of strategic planning and marketing initiatives.  He has gained extensive knowledge in product launches and forecasting in multiple sclerosis, oncology, and dermatology.  Kevin has operational expertise in manufacturing, medical affairs, and pharmacovigilance, He brings a fresh perspective to problem solving and is an extremely valuable member of the RxC team. 

Prior to joining RxC, Kevin was a management consultant at Novumed Live Sciences.  He worked in the Corporate Development at Gilead Sciences and as a research assistant with Oregon Health & Science University.  

Kevin is fluent in German.  He has a B.S. in Biochemistry and an M.S. in Cellular and Molecular Biology from Oregon State University.



Melissa Morales, Analyst 

“The RxC team is so supportive and knowledgeable, and I am extremely lucky to work alongside such experienced and intelligent professionals to develop client presentations with deep analysis and research.” 

Melissa Morales has experience in marketing and sales in the life sciences sector.  Since joining RxC, Melissa has worked on strategic market assessments and patient treatment flow models. She has provided support on a number of primary research and corporate development initiatives. Most recently, she developed a patient flow model to assess the market opportunity for a respiratory product launch in US, Europe, and Canada.  

Melissa received a B.S. from Cornell University in Biological Engineering with a concentration in Biomedical Engineering.



Laura Prout, Office Manager

“I believe a well-run organization like RxC has a direct and positive effect on client experiences.” 

Laura Prout joined RxC in April 2016.  As office manager and executive assistant, Laura provides administrative support for the RxC leadership team.  She oversees human resources management and collaborates with partners on internal projects, including IP development, and marketing. 

Laura brings to RxC, over 15 years’ experience in recruiting and human resources, management consulting, and administrative services.  Prior to joining RxC, Laura was employed with and contracted for Accenture, as a manager in their Change Management practice.  

Laura holds a B.A. from Boston University and an M.S. from Rensselear Polytechnic Institute, both in Psychology.   



RxC Executive Advisors


 Carl Accettura, Executive Advisor

 "My passion is to help clients manufacture and commercialize pharma products with virtual, capital-efficient models and global launch roadmaps. Advanced planning of long lead-time, manufacturing and supply chain readiness is critical to rapid, yet cost-effective, launch success.  Roadmaps guide advanced commercial readiness through effective global and regional development plans and regulatory filings."

Carl has extensive expertise building commercialization readiness globally for pharmaceutical product launches.  He has an unparalleled breadth of expertise in global pharmaceutical supply chain and manufacturing excellence. He offers direction, guidance, best practices and thought leadership to RxC clients. He has overseen the development of end-to-end supply chain strategies, operations excellence, and product launches across the US, Europe and Asia. 

Carl has held senior executive positions at Pfizer, Roche, and BMS. He has successfully launched billion dollar drugs, including Pfizer’s Procardia XL, Diflucan, Norvasc, Zithromax, Zoloft & Cardura, Roche's Hivid and Invirase, as well as Anesta's Actiq and Dainippon Sumitomo Pharma America/Sunovion's Latuda.  At Roche, the life-saving launch of Invirase therapy in less than 24 hours, working cooperatively with major wholesalers, received the HDMA DIANA award for this breakthrough thinking and record breaking release of Invirase to AIDS clinics.  Carl is a sought out speaker at many industry conferences and speaks each semester at the Cornell University Enterprise Engineering Seminar.

Carl has earned a B.S. with distinction from Cornell University in Mechanical Engineering. He also holds a M.S. from University of Illinois and a M.B.A. from the Stern School at New York University.



Grannum Sant, M.D., FRCS, FACS, Executive Advisor

Grannum Sant joins RxC with over 25 years’ industry experience. As a Senior Advisor, Grannum is sought after for his sage advice and experience on topics related to rare diseases, oncology, urology, biotechnology and clinical trials. Grannum is regularly involved with RXC as a subject matter expert. He has a long and established track record of bringing experience, and strategic focus to every situation. As a biopharmaceutical physician, Grannum provides a significant advantage around treatment development opportunities, new product commercialization, and regulations and compliance in life sciences.

Grannum has led many organizations in the areas of Medical Affairs, Oncology, and Urology. Prior to his relationship with RxC, Grannum consulted for Dicerna pharmaceuticals. During his extensive career Grannum was Senior Director, VP and Head, or Medical Director at OPKO Health, Genzyme, Sanofi US, Sanofi Aventis, and Sanofi Synthelabo. Grannum is a Professor at Tufts University School of Medicine.

Grannum holds the following degrees, distinctions and honors. B.A. in History; M.B., B.Ch., B.A.O. with honors in Medicine; and Doctor of Medicine (M.D.) from Trinity College, Dublin, Ireland. Residencies at Albert Einstein College of Medicine of Yeshiva University in General Surgery; and Tufts University School of Medicine in Urology. He holds an FRCS from Royal College of Surgeons in General Surgery.



John Harrington, Executive Advisor

“I have a deep belief to help deliver value to the patients, providers and payers in a changing global healthcare market. I am especially in tune with issues of how strategy gets turned into action and the human dynamics of change management.”

John Harrington provides advisory services to RxC clients related to general management and high level commercial planning issues.  He has executive leadership experience in commercialization, product launch and sales for many pharmaceutical businesses including, oncology, diabetes, endocrinology, cardiology, rheumatology, hematology, and managed care. 

Most recently, John was Senior Vice President and Chief Commercial Officer at Sanofi and has held multiple executive level positions at Sanofi and Sanofi-Aventis, including VP for Primary Care, Diabetes and Oncology business units where John formed and lead the first general medicine business unit for Sanofi’s US affiliate.

John sits on the National Patient Advocate Foundation board, and is an alumnus of Somerset Medical Center Board of Directors, Somerset NJ.  John is a graduate of Stonehill College with a B.A in Economics and an M.B.A from Rockhurst University.



Jim Molt, PhD, Executive Advisor

"Actively listen. The best communicators are the best listeners."

Jim has over three decades of global regulatory experience as an expert in scientific interaction with the U.S. Food and Drug Administration. He provides deep expertise and counsel to RxC and its clients as an Executive Advisor. He has a deep understanding of the regulatory systems in all major markets including US, Europe, and Japan. 

Most recently, Jim was the Global Head of Regulatory Affairs and Senior Vice President Regulatory Affairs, Quality Assurance and Risk Management for US and Europe at Daiichi Sankyo.  He has served as lead regulatory liaison for major product approvals including:  Syprine (one of the first Orphan drugs), Pepcid, Prilosec, Taxotere, Rilutek, Prilosec OTC, Benicar, and Effient. Jim also held positions of increasing responsibility in regulatory affairs, quality assurance, and risk management in major pharmaceutical companies including Merck, RPR, Nycomed, and AstraZeneca. 

He holds a Ph.D. in Physiology, with a minor in Statistics from Cornell University, and a B.A. in Biology from Colgate University.



Jim Smeeding, RPh, MBA, Executive Advisor

Jim Smeeding, RPh, MBA, is the former executive director of the National Association of Specialty Pharmacy (NASP). He is also a founder of the Center for Pharmacoeconomic Studies at the University of Texas College of Pharmacy. His research interests are in applied pharmacoeconomics, systems integration and managed care. His pharmacy degree is from the University of Buffalo and his MBA from the University of Texas. Over the past 40 years his practice orientation has been in hospital pharmacy, clinical services design, home infusion therapy, managed care services, and disease management.

Jim is the President of the JestaRx Group a HEOR consultancy that has worked with all major pharmaceutical companies. He is also the Executive VP and founder of Engaged Media a technology driven patient engagement solution used in multiple copay programs. As President of the National Payer Roundtable, Smeeding stays in contact with the Chief Medical Officers and Chief Pharmacy Officers of national and regional health insurers. His hospital pharmacy consultancy practice, Project Rx offers management services to hospitals and hospital groups throughout the US. He has also been active in Cannabis Based Medicines (CBM) research as a founder of CannaPharma Rx.

Jim’s private clients through his Edjudicate LLC, constitute the spectrum of pharmaceutical companies, medical device companies, diagnostic testing and all classes of pharmacy affairs – hospital, retail, chain, managed care, academic and research. His broad expertise in professional affairs has allowed his clients to understand, approach and impact medical and pharmacy affairs from product selection through to the value proposition as well as professional communications, patient communications and safety. Jim is widely known for his broad interests and his ability to moderate a program to bring out cogent learning points and make the educational program applicable to practice.